← All trials
NCT05824858
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2023
- Primary completion
- Jun 17, 2023
- Completion date
- Jun 17, 2023
- First posted
- Apr 24, 2023
- Last posted
- Sep 29, 2023
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eli LillyLead sponsor
- Loxo OncologyCollaborator
- Loxo OncologyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.